CureVac’s Stock Market Journey Concludes Following BioNTech Acquisition

CureVac NL0015436031

The final chapter for Tübingen-based mRNA pioneer CureVac on public markets is now written. A turbulent period in German stock market history, which began with significant promise during the vaccine race, will formally end on January 16, 2026, when its shares are permanently removed from the Nasdaq exchange. This follows the company’s $1.25 billion acquisition by its rival, BioNTech.

For investors, the transition is largely complete. Those who accepted the exchange offer received 0.05363 BioNTech American Depositary Shares (ADS) for each CureVac share they held. At the time the deal was announced, this ratio represented an approximate 55% premium to CureVac’s average trading price.